MLSS · XBRL financial data

Milestone Scientific financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MLSS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	1,816	3,993	3,905	3,035	2,195	2,566
Gross profit	3,621	6,312	4,901	6,793	6,435	6,408
Research and development	308	878	1,150	701	859	449
Selling, general and administrative	10,767	12,738	12,514	13,136	12,295	11,577
Total operating expenses	11,074	13,690	13,728	13,899	13,192	12,104
Operating income (loss)	(7,453)	(7,379)	(8,827)	(7,106)	(6,757)	(5,697)
Other income (expense)	(25)	—	—	—	—	—
Income tax expense (benefit)	16	0	0	0	—	—
Net income (loss)	(7,337)	(6,818)	(8,706)	(6,929)	(4,714)	(5,722)
Earnings per share, basic USD per share	(0.12)	(0.10)	(0.12)	(0.10)	(0.06)	(0.07)
Earnings per share, diluted USD per share	(0.12)	(0.10)	—	—	(0.06)	(0.07)
Weighted average shares, basic thousands of shares	63,061	68,830	70,607	72,776	79,791	82,064
Weighted average shares, diluted thousands of shares	63,061	68,830	—	—	79,791	82,064

Fiscal years (MLSS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	14,224	14,764	8,715	2,978	3,258	1,113
Short-term investments	13,100	13,900	8,700	—	—	—
Marketable securities	—	—	0	2,977	0	—
Accounts receivable	1,081	943	694	313	475	—
Inventory	2,420	1,542	1,792	2,638	3,713	3,782
Prepaid and other current assets	416	375	444	518	565	469
Total current assets	18,555	18,934	12,971	10,794	9,287	7,478
Property and equipment, net	31	24	18	10	13	19
Right-of-use asset	632	551	444	355	258	150
Total assets	19,571	19,810	13,702	11,372	9,797	7,806
Accounts payable	483	780	1,103	—	—	—
Accrued liabilities	824	1,417	1,125	1,512	1,796	—
Total current liabilities	2,878	3,097	3,300	3,077	3,744	4,131
Lease liability, non-current	558	477	385	282	166	35
Total liabilities	3,464	3,594	3,696	3,359	3,964	4,994
Accumulated deficit	(100,886)	(107,704)	(116,410)	(123,340)	(128,053)	(133,775)
Total stockholders' equity	16,201	16,368	10,226	8,013	5,833	2,813
Total liabilities and equity	19,571	19,810	13,702	11,372	9,797	7,806
Common shares outstanding (cover page) thousands of shares	66,559	68,120	69,999	76,602	78,380	80,453

Fiscal years (MLSS's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,337)	(6,818)	(8,706)	(6,929)	(4,714)	(5,722)
Stock-based compensation	550	791	1,499	1,467	1,345	953
Depreciation and amortization	96	74	64	62	—	—
Net cash from operating activities	(6,985)	(4,018)	(6,032)	(5,326)	(2,920)	(2,917)
Purchases of property and equipment	21	15	9	—	10	15
Net cash from investing activities	(21)	(15)	(9)	(2,972)	2,966	(15)
Proceeds from issuing common stock	18,043	0	0	2,570	—	—
Net cash from financing activities	19,714	4,573	(9)	2,561	234	786
Net change in cash	12,708	540	(6,049)	(5,738)	280	(2,145)

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Vicarious Surgical	1,407	not reported	(6,325)	not reported	0.6 quarters	Q1 FY26 10-QMar 31, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Modular Medical	3,920	not reported	(5,972)	8.2M	0.7 quarters	Q1 FY27 10-QJun 30, 2026
HeartBeam	8,722	not reported	(3,342)*	56.3M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.